Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication

Paul Lochhead, Aya Kuchiba, Yu Imamura, Xiaoyun Liao, Mai Yamauchi, Reiko Nishihara, Zhi Rong Qian, Teppei Morikawa, Jeanne Shen, Jeffrey A Meyerhardt, Charles S Fuchs, Shuji Ogino

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

BRAF mutation in colorectal cancer is associated with microsatellite instability (MSI) through its relationship with high-level CpG island methylator phenotype (CIMP) and MLH1 promoter methylation. MSI and BRAF mutation analyses are routinely used for familial cancer risk assessment. To clarify clinical outcome associations of combined MSI/BRAF subgroups, we investigated survival in 1253 rectal and colon cancer patients within the Nurses' Health Study and Health Professionals Follow-up Study with available data on clinical and other molecular features, including CIMP, LINE-1 hypomethylation, and KRAS and PIK3CA mutations. Compared with the majority subtype of microsatellite stable (MSS)/BRAF-wild-type, MSS/BRAF-mutant, MSI-high/BRAF-mutant, and MSI-high/BRAF-wild-type subtypes showed multivariable colorectal cancer-specific mortality hazard ratios of 1.60 (95% confidence interval [CI] =1.12 to 2.28; P = .009), 0.48 (95% CI = 0.27 to 0.87; P = .02), and 0.25 (95% CI = 0.12 to 0.52; P <.001), respectively. No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P interaction > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification.
Original languageEnglish
Pages (from-to)1151-1156
Number of pages6
JournalJournal of the National Cancer Institute
Volume105
Issue number15
DOIs
Publication statusPublished - 22 Jul 2013

Fingerprint

Microsatellite Instability
Colorectal Neoplasms
Mutation
CpG Islands
Confidence Intervals
Microsatellite Repeats
Phenotype
Health
Rectal Neoplasms
Tumor Biomarkers
Colonic Neoplasms
Methylation
Nurses
Survival
Mortality
Neoplasms

Cite this

Lochhead, P., Kuchiba, A., Imamura, Y., Liao, X., Yamauchi, M., Nishihara, R., ... Ogino, S. (2013). Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. Journal of the National Cancer Institute, 105(15), 1151-1156. https://doi.org/10.1093/jnci/djt173

Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. / Lochhead, Paul; Kuchiba, Aya; Imamura, Yu; Liao, Xiaoyun; Yamauchi, Mai; Nishihara, Reiko; Qian, Zhi Rong; Morikawa, Teppei; Shen, Jeanne; Meyerhardt, Jeffrey A; Fuchs, Charles S; Ogino, Shuji.

In: Journal of the National Cancer Institute, Vol. 105, No. 15, 22.07.2013, p. 1151-1156.

Research output: Contribution to journalArticle

Lochhead, P, Kuchiba, A, Imamura, Y, Liao, X, Yamauchi, M, Nishihara, R, Qian, ZR, Morikawa, T, Shen, J, Meyerhardt, JA, Fuchs, CS & Ogino, S 2013, 'Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication' Journal of the National Cancer Institute, vol. 105, no. 15, pp. 1151-1156. https://doi.org/10.1093/jnci/djt173
Lochhead, Paul ; Kuchiba, Aya ; Imamura, Yu ; Liao, Xiaoyun ; Yamauchi, Mai ; Nishihara, Reiko ; Qian, Zhi Rong ; Morikawa, Teppei ; Shen, Jeanne ; Meyerhardt, Jeffrey A ; Fuchs, Charles S ; Ogino, Shuji. / Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. In: Journal of the National Cancer Institute. 2013 ; Vol. 105, No. 15. pp. 1151-1156.
@article{dbdc79365f804a27a2a08c7435a2a26c,
title = "Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication",
abstract = "BRAF mutation in colorectal cancer is associated with microsatellite instability (MSI) through its relationship with high-level CpG island methylator phenotype (CIMP) and MLH1 promoter methylation. MSI and BRAF mutation analyses are routinely used for familial cancer risk assessment. To clarify clinical outcome associations of combined MSI/BRAF subgroups, we investigated survival in 1253 rectal and colon cancer patients within the Nurses' Health Study and Health Professionals Follow-up Study with available data on clinical and other molecular features, including CIMP, LINE-1 hypomethylation, and KRAS and PIK3CA mutations. Compared with the majority subtype of microsatellite stable (MSS)/BRAF-wild-type, MSS/BRAF-mutant, MSI-high/BRAF-mutant, and MSI-high/BRAF-wild-type subtypes showed multivariable colorectal cancer-specific mortality hazard ratios of 1.60 (95{\%} confidence interval [CI] =1.12 to 2.28; P = .009), 0.48 (95{\%} CI = 0.27 to 0.87; P = .02), and 0.25 (95{\%} CI = 0.12 to 0.52; P <.001), respectively. No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P interaction > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification.",
author = "Paul Lochhead and Aya Kuchiba and Yu Imamura and Xiaoyun Liao and Mai Yamauchi and Reiko Nishihara and Qian, {Zhi Rong} and Teppei Morikawa and Jeanne Shen and Meyerhardt, {Jeffrey A} and Fuchs, {Charles S} and Shuji Ogino",
year = "2013",
month = "7",
day = "22",
doi = "10.1093/jnci/djt173",
language = "English",
volume = "105",
pages = "1151--1156",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication

AU - Lochhead, Paul

AU - Kuchiba, Aya

AU - Imamura, Yu

AU - Liao, Xiaoyun

AU - Yamauchi, Mai

AU - Nishihara, Reiko

AU - Qian, Zhi Rong

AU - Morikawa, Teppei

AU - Shen, Jeanne

AU - Meyerhardt, Jeffrey A

AU - Fuchs, Charles S

AU - Ogino, Shuji

PY - 2013/7/22

Y1 - 2013/7/22

N2 - BRAF mutation in colorectal cancer is associated with microsatellite instability (MSI) through its relationship with high-level CpG island methylator phenotype (CIMP) and MLH1 promoter methylation. MSI and BRAF mutation analyses are routinely used for familial cancer risk assessment. To clarify clinical outcome associations of combined MSI/BRAF subgroups, we investigated survival in 1253 rectal and colon cancer patients within the Nurses' Health Study and Health Professionals Follow-up Study with available data on clinical and other molecular features, including CIMP, LINE-1 hypomethylation, and KRAS and PIK3CA mutations. Compared with the majority subtype of microsatellite stable (MSS)/BRAF-wild-type, MSS/BRAF-mutant, MSI-high/BRAF-mutant, and MSI-high/BRAF-wild-type subtypes showed multivariable colorectal cancer-specific mortality hazard ratios of 1.60 (95% confidence interval [CI] =1.12 to 2.28; P = .009), 0.48 (95% CI = 0.27 to 0.87; P = .02), and 0.25 (95% CI = 0.12 to 0.52; P <.001), respectively. No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P interaction > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification.

AB - BRAF mutation in colorectal cancer is associated with microsatellite instability (MSI) through its relationship with high-level CpG island methylator phenotype (CIMP) and MLH1 promoter methylation. MSI and BRAF mutation analyses are routinely used for familial cancer risk assessment. To clarify clinical outcome associations of combined MSI/BRAF subgroups, we investigated survival in 1253 rectal and colon cancer patients within the Nurses' Health Study and Health Professionals Follow-up Study with available data on clinical and other molecular features, including CIMP, LINE-1 hypomethylation, and KRAS and PIK3CA mutations. Compared with the majority subtype of microsatellite stable (MSS)/BRAF-wild-type, MSS/BRAF-mutant, MSI-high/BRAF-mutant, and MSI-high/BRAF-wild-type subtypes showed multivariable colorectal cancer-specific mortality hazard ratios of 1.60 (95% confidence interval [CI] =1.12 to 2.28; P = .009), 0.48 (95% CI = 0.27 to 0.87; P = .02), and 0.25 (95% CI = 0.12 to 0.52; P <.001), respectively. No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P interaction > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification.

U2 - 10.1093/jnci/djt173

DO - 10.1093/jnci/djt173

M3 - Article

VL - 105

SP - 1151

EP - 1156

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 15

ER -